we're very pleased sanofi is the potential acquirer of the company.e think they really do appreciate all of the technology and assets we have and we look forward to working with them >> you seemed to get a massive premium on that price ever at first discussion about a takeover i mean, do you really think your company is worth what they're paying? >> i think we've had a tremendous ride. i think you'll note that in october we had fantastic results with the most advanced components we hope will get to market this year we had a very successful ipo in the back end of october raising over $30 million and now, as you say, we've obviously been pushed in the spot light and people are able to assess what we have as pr programs but technology. we certainly hope people realize what sanofi have >> for those who don't follow it as closely as you do, what is it about them that makes it so desperate to buy you >> we have antibodies. they've been adapted for use in the pharmaceutical industry because they're very specific and high have efficacy in belgium, with animal

for included the target sanofi as well. guy: thank you, manuel.plenty of stuff for our team to get their teenth into. find it on your bloomberg. we talked a little bit about europe. you talked about the individual spaces from a geographical point of view. where else do i go? >> i still think banks and commodities and resources and materials. the commodity mom has been quite impressive. -- the commodity boom has been quite impressive. it is a little bit richer in the near-term. the risk is if oil comes back from the levels, we see weakening. sectorshe two clear to stand at our commodities and financial regulators. matt: if i look at year to date 600bdd break down the stoxx by the sectors, you still see auto-parts wailing on everybody else, up 0.2% this year. why do you think that is, and it does that continue? >> i think it does. i think the auto sector looks very strong, but that is not a european story. if you look at the u.s. auto story as well, it is a similar structure. so, yes we like the alternative. that is a store that again, we think coul

joe, how is the market going to take the sanofi news? reporter: it is huge is for sanofi.o-nordisk with a company that was seen to be purchasing this stock. it is a big shock for the market. move andthe shares to also, obviously sanofi as well. 3.9 billion euros, a massive deal for the market today. manus: i wonder about ams. we are seeing calls for this stock, which is a swiss electronics technology solutions stock. it could be up 25% at the open. what is the story? reporter: yes, this is a technology maker. they have a lot of big clients, like apple and companies like that. they issued this trading update, which the bank has taken very positively today. we are hearing very good calls on that. , a stock could rise 25% massive move up. the market has reacted very well to that this morning. guy: that is interesting, in burgerf whatd dani just told us on the quant stocks. if you are looking at what is happening with gkn, how do you take some chips off the table question mark is a chips off the table story? has been well, melrose very aggressive during the situation and has b

also looking at sanofi.'s going to a $11.6 billion for hemophilia drug maker, a french drug maker. and their shares up, oh, my god, shares really climbing up early 63%. sanofi extending losses, 3.74%. the idea here is that sanofi is paying a pretty hefty premium for dick vermeil. and also in this merger monday raziness, celgina greed to buy genotherapeutics. the goal here is to expand its offerings in a very hot cancer therapy market. juno therapeutics up more than 27%. celgene down more than 1%. david: it's a wild merger monday. but going back to a.i.g.t. does strike me that they should break it up, so they don't have the designation anymore. and now they're going to start acquiring it, as you say, that's a beg turnaround. lisa: that's what i'm looking at right now, for them to take their cash and buying a reinsurance company and just to be clear, this comes at a time when reinsurance is frankly becoming ever more important, especially with all the storms that we've been seeing, you know, these insurance co

finally, a belgian company being bought by sanofi for $4.8 billion. sin if you getting further into treatments for blood disorders with this deal and beating out novo nordisk. i mentioned what's going on with rates. an important story as we see the dollar rally. we have not seen that level on the 10 year yield since 2014. crude oil falling and gold futures falling as well as we see the dollar and rates push higher. mark: just getting some breaking lenderussia's biggest has held talks with possible investors for its wholly-owned turkish units as russia's biggest lender considers a cell. this is according to people familiar with the matter. holding discussions with possible investors including dubai, emirates, and other gulf-based lenders. that is according to people who say the talks are private. discussions are at an early stage and may not result in a deal. sberbank has been under sanctions since tony fo 2014. was turkey's ninth biggest lender. that's according to the countries banking association. breaking news crossing the bloomberg terminal from r

njer: sanofi has agreed to purchase seven point $6 billion.e hemophilia drug maker bioverativ at $105 per share in a 60% premium over the closing price on friday. richment is offering 2.7 billion euros. event complete control over the finance business. richemont already owns about 50% of the unit. more of the subsidiaries halted the stock from training pending .major announcements most of the subsidiaries halted the stock from trading pending major announcements. says theelecom's ceo fifth generation of wireless technology will be a revolution for his industry. tim cook bloomberg the company will be able to provide dedicated software platforms for the president. i will benefit from andrew sharing. he also hates the made in the u.s. and the positive impact the republican stepped inside. it is not something that is just regulated. text reform. we have a monetary policy decision from the bank of japan. in on thursday, it is the ecb's term. t.at is what we call the recep you listening. i want to put a litter on the smb said before, it is all about

sanofi down about 3.5% one more tieup to tell you about.g is to buy reinsurer validus for $5.56 billion. it will imimmediately add to the earnings. >> the government shutdown the government is set to vote on a funding bill to get the lights back on. kayla tausche joins us with more hey, kayla >> hey, wilf they're shortening the time frame for government funding to february 8th it restores the children's health insurance program and it carries a pledge from senate majority leader mitch mcconnell to take up an immigration deal before the new february 8th deadline if there isn't a bipartisan deal before then mcconnell said he would make time in his schedule for immigration legislation. that's a move senator lindsey graham who's part of the centrist group leading talks called, quote, more than reasonable mcconnell said the government would have to open first >> the shutdown should stop and we'll soon have a vote that will allow us to do exactly that. let's step back from the brink let's stop victimizing the american people and get back to work

dollars, 105 in cash, to buy on friday the "wall street journal" joins us more strategic move, by sanofi been under a lot of pressure had a series of service sales acquisitions, or attempted acquisitions i should say, in recent years. and does seem to be coming under a lot of precious from competition as gesneric for one we produced has made this move, share price reaction was not so favorable for sanofi but you can see in u.s. premarket trading that premium does seem well liked by investors. in u.s. >> final couple seconds here saudi arabia says wants opec to look beyond this year's deal to cut back production. >> talking about moving into 2019 beyond, really the idea seems to be to repair confidence even though oil prices absolutely jumped this year, you need a fair degree of confidence among market participants this is going to last in order to really invest in longer term infrastructure projects, so starting to look beyond the end of the year, possible cooperation on pricing. >> "the wall street journal" thank you. >> thanks for having me. >> all right now we are going to say good mo

sanofi is purchasing new products to offset declines for its best selling lantus which faces cheaperpetition. just want to show you what's happening to the euro today. as you can see, we are up against the dollar by a quarter the threeering around year high. 12264 is the close from last monday which was the three-year high. big event over the weekend in germany. entering into negotiations with merkel led blocker. they got to vote on the vinyl packed. it was a close run thing. if the euro rises this week it will be the sixth consecutive weekly gain which would be the best run since 2014. i a lot could depend on the ecb on thursday. there's going to be a possibility that mario draghi say a faster pace of your appreciation will risk weighing on inflation. we await the ecb on thursday. vonnie: a little volatile today. we are talking two or three percentage points when it comes .o the vicks movement that is not a bad thing. right now it is perched at 11. unclear if the shutdown is having an impact on market sentiment. there was a lot of all you can treasure each -- volume in treasury trad

sanofi looking to offset some of those that of theen fading because insulin drug. that is the backstory. 100 five dollars per share in cash. a 64% premium. let's talk about the broader market action because the u.s. shutdown is entering its third day, one of the big stories for markets. markets seem to be shrugging that off. we have the s&p futures pointing by .1%. the stocks market over in asia has been pretty mixed. we failed to make progress in the senate and that will be the focus of our conversations. the dollar index, pretty stable with that in mind. balance in thehe euro. 6351, moving higher after last week's selloff. 20 more from the russian and saudi oil ministers. cooperation after 20, what does that mean for production cuts? matt? matt: you talk about the euro. if you take a look at the chart, on the bloomberg, you can access this with your own terminal. g #btv 9576. d up a little bit. we have been hovering at 122 and change for a couple of sessions now. points out there is a bearish technical indicator going on right now and you have bearisheuro showing

it seems to be like sanofi gets ablynx. of biotech power. ♪ taylor: let's get to bloomberg business flash. sanofi has beaten out a bitter rival to purchase ablynx. the prices for $.8 billion. that is more than an unsolicited offer from novo nordisk's. it will give sanofi and potential blockbuster drug. minute, novo said it will not make a last bid. cryptocurrency heist has called for tighter regulation. on friday someone hacked into coin check and stole almost $500 million in digital tokens. that is your ebf. -- that is your bloomberg business flash. tom: michael mckee has been a student of nafta and trade. as we consider the state of the union and trade . michael, the president had comment in davos on trade. he is looking for a bipartisan approach which means america, this is the way we are going to do it, if you want to come on board, great. does canada, mexico and nafta, do they feel the same bipartisan davos.co --eard in davos? michael: they are much more bilateral. if you did what he said you should do as a leader of a

sanofi does not want to be allealle allergan >> 105 as i told you, $11.6 billion.n this one, there was not any news out and, get this, it is about 8.4 times 2018 estimated revenue and put into perspective of what we just told you of peak revenues for the celgene deal, you see it much higher it is at least what they are saying of 2016 could close quickly, sanofi, they went after innovation, they failed there. >> they had decent franchise and orphan drugs and things of that nature the analysts that weighed in already, generally seemed positive and some questions of evaluations. >> have anyone seen bioverativ products >> i have not. >> they have literally something so powerful. this is from biogene where people feel it is not enough they create avid lab i didn't think they worth that much given the fact that they are creatorcreators >> there >> and the aig deal, it is been the worst performing in major insurance company. aig had problems with care, too. i think ge have to do another downgraded ge. >> another 17 target >> they chose not to downgrade it yesterday with b

sanofi said that bio verativ would boost its sales in treatment and drugs associated separately, sharesn gambling firms including william hill are under pressure this follows a report on this week "the new york times" stakes on betting shops will be lilted to two pound sterling. regulators have expressed concerns that these so-called fixed terminals are especially addictive. dixons car phone tightened its profit reporting a 6% jump back in the christmas period strong demands your iphones helped boost the market. performance strong in other markets including norway and greece that seems like the time to bring in mike ingram, a chief strat jieft gis strategist you don't see bullish on uk profits? >> no, that's been brought out in the performance to date i was interested to hear when suggested the worst of the brexit fears are actually behind us in fact, i feel very different in fact, the politicians in the uk say nothing is agreed until everything has been agreed this is an economic process with economic consequences. even though the market responded quite positively to the end of the fir

quite a turnaround for prince alwaleed in the last week sore so >>> some stocks to patch, sanofi strikingeal to buy bio-tech firm ablynx, about a 21% premium on friday. the deal comes after a lower offer from novo nordisk. >>> and group of investors calling on avon products to consider putting itself up for sale "the wall street journal" reports the group which owns a combined 3% of the company plans to send a letter to the board. they believe a multiyear long effort to turn around that brand has failed and requires new leadership it's up 2.5% >> the head of ford china's division has quit after just five months on the job, citing personal reasons his departure is a blow for the auto leader. ford china sales fell 6% last year, compared to the 3% rise for the broader industry overall. >>> still ahead on "worldwide exchange," the big business of bots >>> plus, more important than fire, that's what google ceo is chlling his red hot part of the te world we'll tell you what it is when "worldwide exchange" returns any object. any surface. if you've got a life you gotta swiffer we use so why do w

sanofi fellrugmaker 3% after they announced a bioverativ.ome traders see the deal as too expensive. this also might affect president trump's trip to devils. diagnosed -- davos. >> he is planning to speak at the world economic forum. meanwhile, oxfam is calling on world leaders to crack down on tax evasion. there is a gap tween the rich and poor that is widening even further. we have this report. --re is a call to oxfam's there is a call to arms in oxfam's inequality report this year. the total wealth created was captured by the top 1% and the bottom 50% of the world got nothing. says wealth inequality is growing and the figures are staggering. the increase in wealth for billionaires was $762 billion. that is enough to end extreme poverty worldwide, not just once but seven times. oxfam is calling for a crackdown on tax havens and date narrowing of the gender pay gap. -- a knowing of the gender pay gap. this womanan is a taxi driver in egypt. .> egypt is unfair it judges women and says they cannot work in a man's profession. egegypt is currere

french pharma ferm sanofi buying a biotech company for $11.6 billion.e have seen $170 billion of across border deals between the united states and european companies in 2017. guys, back to you. >> thank you very much when we come back, about 30 minutes to go until that senate vote that could end the shutdown stanford university director of domestic policy lanhee chen joins us to weigh n and the s&p 500 on the track for the best january since 1997 the dow is just about flat a this point "squawk alley" back right after this >>> hello, everyone. here's your cnbc news update at this hour. japan has spotted a north korean ship obtaining oil in defiance of united nation's sanctions a patrol plane spotted the tanker on saturday saddled up to another tanker with a registry in the dominican republic. tokyo officials conducting a missile attack drill to prepare that city for the possibility of a north korean strike. 350 people participated. and when the alarm sounded, they took cover in underground locationors buildings. it is the first such drill to take place i

sanofi launches a takeover bid to purchase that for 45 euros per share.r breaking news headline. you have got the bid on the m&a. the five year government bond yields touch zero, the highest 2015. there are a couple things happening in the markets. definitely really beginning to move these markets. we will hear from global investors shortly. in the meantime, let's get to the bloomberg flash. hare will usensh its own capital to reimburse customers. the tokyo-based company says it will repay all 260,000 users impacted. s forrate of 82 u.s. cent each of the 523 million coins stolen. japanese policymakers who introduced legislation last april to prevent such disasters and put pressure on the global grid markets where he -- global theto markets wary of cryptocurrencies. after allegations that the chairman sexually harassed women. morgan stanley downgraded their rating. the wall street journal reported that the former resort manicurist performed sexual acts. the allegations were denied. on friday, shares in the company's u.s. parent fell 10%, the most in 13 mon

an awful lot of work we'll see if they get it >>> some other stocks to watch, sanofi looking to buy bioverativ premium for the friday closing price. bioverativ makes drugs to treat hemophilia. making a new offer until next month. it's said to be keeping its options open on its shares online lender so far has offered its ceo job to twitter according to sources, terms haven't been solidified but announcement is likely in the next few days. >>> still ahead on "worldwide exchange," is good luck good we'll talk about a statement in washington in terms what that could mean for your money on wall street. >>> and the u.s. equity futures right now are under a bit of pressure as we enter day three of the shutdown. dow jones industrial average indicating they will open lower by 57 points stay tuned you're watching "worldwide exchange" right here on cnbc is the best way to get that fish to your plate safely. (dane chauvel) sometimes the product arrives, and the cold chain has been interrupted, and we need to be able to identify where in the cold chain that occurred. (tom villa) we took our world class net

. >>> sanofi striking a deal to buy ablynx, $2.6 billion sanofi paying 20% of the closing price on friday. that deal coming after ablynx had rejected a bid from novo nordisk earlier. >>> and shares of wynn macau down more than 6% in hong kong win resorts down again slightly premarket. the top of 10% after "the wall street journal" published the sorry of dozens of allegations of sexual misconduct by wynn contest that brewer is here. >> the wynn resorts launching their own allegations against steve wirn the only women on the board who chaired the compliance committee has been tapped to lead the inquiry. we'll told it will include outside counsel. and the republican national committee has accepted sieve wynn's resignation with a very brief statement. steve wynn is largely seen as the emperor of this company that bears his name making the decisions even to the tiniest details even on room design. wynn has called these accusations preposterous he blamed his ex-wife elaine wynn for sparking these comments the journalist who broke the story said she was not behind it the company has raised a sta

and sanofi is taking a little hit as some value the competition.gene buying june notice therapeutics giving it a foothold in the burgeoning space of cancer immuno therapy. both of these deals are boosting biotech stocks is and speculation that more m&a will follow the companies with the biggest piles of cash is gilead, merck, j&j according to baird from clovis oncology to bluebird, which we're seeing that stock up quite a bit. people hope those deals are coming back in 2018 for biotech. >> we just said the best start to the area since 2007. >> big start. >>> up 115, record territory for all the major averages we have the closing countdown in a moment. >>> as we head to break, here's another check of those netflix shares company gearing up to report fourth quarter earnings in a few minutes. it'sp reha umo tn 3% heading into the close you're watching cnbc, first in business worldwide driving specific sectors of out performance. where a rising middle class powers a booming auto industry. a leap into the digital era draws youthful populations to mobile

. >> well, french drugmakerer sanofi shopping for u.s.ioverativ more than 11 billion dollars, 105 a share in cash 64% premium biobioclosed friday, makes drugs to treat hymn kneelia shairz sanofi under pressure they tried this before investors skepticed cal bioverativ soaring up more than 60%. >> amazon opening a cashierless store today in seattle, all powered through artificial intelligence the amazongo store downtown seattle remember they viewed the concept a year ago waiting for store to open you go in scan your app, on your phone, go pick out what you want, walk out the door. no conversation needed, shares amazon up 60% from a year ago don't say good morning hello good-bye to anybody. >> if you know that is right --, believe it or not, interesting concept what do you think the widespread of the -- cashierless not only for horizon other companies. >> amazon leading the way anything course of 20 years worked, wording well for them i think the way consumers get products is changing, completely amazon changed that sit on couch order, walk

in both cancer and in your drug dupixint, cancer adding a billion dollars with the investment with sanofi's a crowded class with a lot of drugs on the market already. how are you going to compete >> there may be a lot of talk in the crowd, but it's pretty early going in immunooncology. we're starting to bend the curve a little bit in the fight against cancer we're really still way early in the innings, i think there's a lot we can do. we have a lot of technology and biology and a great product we'll be submitting we think to the fda this quarter we hope it will be approved this year and we should be off to the races. >> reporter: if there are multiple regimens on the market competing with each other, do you compete on price >> you know, we're a company that always feels that price should be part of the things you compete on obviously first you like to compete on the fact that you have a product where you've shown something that nobody else has. for example, this particular drug, although it's in a class of these so-called pd-1 blockers, we're the first company that's got data we think wil

sanofi agreeing to acquire ablynx the global bond selloff also continues.e a look at the german five year yield touching positive territory for the first time since late 2015 on this expectation that central banks will begin unwinding stimulus. and this expectation of this unwinding that has resulted in the euro gaining momentum against the u.s. dollar. yes, slightly lower today. but still up 3% for the year take a look at the uk pound. higher by 4% in 2018 though some analysts saying the trajectory could being complicated by uncertainty around uk politics 140 for the pound. back to you. >> thank you >>> and some controversy meanwhile over fitness trackers making news this morning are the devices and apps revealing sensitive military information nbc's ha ns nichols has the latest. >> there is a global heat map that is pout out where you can compare and compete with fellow runners or bikers. the issue is that a lot of u.s. military personnel use it. they've been using it and not turning off the settings when down range, when they're in places like the kandah

the french drug-maker sanofi is buying a drugmaker for more than $11 billion.bullish signal. state on the market. bring in jason rotman, head of lido isle advisors. jason this shutdown is having little or no effect on the market. i expect this to continue. how about you? >> the only effect really which has been minimal has been on the bond market. yields have been trending higher over the past few weeks. over the weekend heading into sunday evening you know the bond futures were open. the prices went lower, yields went high ear little bit, maybe a small stick in the confidence of bonds. they went right back up. the stock market is basically even today. i think overall the market is going to be quiet looking ahead at the fed meeting which is next week. we'll see what netflix and various earnings do this week. nothing is that bearish so far. stuart: jason, hold on a second. i want to look at general electric, the once almighty stock, hitting hard times recently. in fact today ge at one point very briefly fell below $16 a share. first time in years it has been dow

sanofi,s, if you take this is a company that has been needing to do a big m&a transaction for a longthere is a lot of logic. lisa: there are also accusations they are vastly overpaying, giving the high equity valuations. you have some seeing this m&a boom and saying it reminds us a lot of 2000 since we saw a big rush of issuance, and we know what happened after that. is this the preceding factor that is going to lead up to the next downturn? ed: it is a great point, and we are seeing these very high premiums. if you look at celgene, it is a 91% premium, one of the highest in the biotech industry. there are some question marks. a lot of the deals that has -- that can be done have been done. if you are a company that wants to acquire investors, you will have to pay up. i am not sure the deal is being done on high risk. so peopleuite tight, are not seeing the deals being out of the box, unexpected trades. david: let's talk interest rates. plots m&a activity against the 10 year yield. the 10 year yield is in blue and as it goes up, mna comes down. -- m&a comes down. how concerned are we?

it's in that very coveted area let's focus on the other deal, the 11.6 billion acquisition about sanofi you're see san on fit getting hit there. it's a 64% premium to friday's close. all of this with the exception of san oy fit boosting the biotech space. if you look at a longer-term chart, it's getting almost up there to the 2015 highs when hillary clinton had that tweet about drug prices. it's going to be the m. & a as a positive versus the threat of drug pricing pressure. >> let's talk flu. >> i know a few things about the flu. >> you have recent personal experience. >> i do. i don't think i had the flu last week flu season is pretty severe this year, if you look at hospital visits with flu-like symptoms, we have a great chart here that shows this year, the blue line is this season it was tracking along with pretty previous severe season, though it's kept going and one thing people are worrying about is people going to work when i was sick. i might have been contagious according to a city md survey 40% of us have gone to work when we thought we had flu-like symptoms. >> i'm surprised